Vivozon Pharmaceutical Co., Ltd. (KOSDAQ:082800)
South Korea · Delayed Price · Currency is KRW 2,900.00
-70.00 (-2.36%)
At close: Oct 23, 2026
Vivozon Pharmaceutical Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 50,344 | 59,343 | 87,601 | 71,318 | 51,564 | 57,560 |
Revenue Growth | -39.54% | -32.26% | 22.83% | 38.31% | -10.42% | 32.04% |
Gross Profit Gross Profit Growth | 18,144 | 24,184 | 45,407 | 31,321 | 21,437 | 19,639 |
Operating Income Operating Income Growth | -18,889 | -19,166 | -1,800 | 4,709 | -9,806 | -19,615 |
Net Income Net Income Growth | -32,826 | -32,424 | -9,982 | -3,357 | -39,906 | -69,457 |
Earnings Per Share EPS Growth | -620.86 | -654.98 | -209.06 | -70.35 | -917.27 | -2130.00 |
EPS Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Korea Korea Growth | 46,819 | 55,937 | 85,338 | 69,788 | 48,255 | 52,334 |
Japan Japan Growth | 385.53 | 346.21 | 400.76 | 264.12 | 77.82 | 2,065 |
People's Republic of China People's Republic of China Growth | 899.57 | 711.49 | 631.75 | 886.35 | 921.12 | 879.14 |
Russia Russia Growth | 431.35 | 342.53 | 185.15 | 277.09 | 213.4 | 419.11 |
Other Other Growth | 1,809 | 2,006 | 1,070 | 1,227 | 2,083 | 1,863 |
Total Total Growth | 50,344 | 59,343 | 87,626 | 72,592 | 51,564 | 57,560 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 10,703 | 5,158 | 9,988 | 17,721 | 26,400 | 64,055 |
Total Debt Total Debt Growth | 33,471 | 42,341 | 36,500 | 41,615 | 60,310 | 84,115 |
Net Cash (Debt) Net Cash Growth | -22,768 | -37,183 | -26,512 | -23,894 | -33,910 | -20,060 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -430.36 | -751.00 | -555.26 | -500.74 | -779.45 | -615.13 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -10,844 | -6,869 | 5,731 | 2,992 | -3,323 | -17,496 |
Capital Expenditures CapEx Growth | -630.86 | -1,412 | -8,450 | -4,523 | -6,491 | -10,111 |
Free Cash Flow Free Cash Flow Growth | -11,475 | -8,281 | -2,719 | -1,532 | -9,814 | -27,608 |
Free Cash Flow Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 36.04% | 40.75% | 51.83% | 43.92% | 41.57% | 34.12% |
Operating Margin | -37.52% | -32.30% | -2.05% | 6.60% | -19.02% | -34.08% |
Pretax Margin | -65.04% | -54.39% | -12.03% | -3.03% | -49.15% | -131.77% |
Profit Margin | -65.20% | -54.64% | -11.39% | -4.71% | -77.39% | -120.67% |
FCF Margin | -22.79% | -13.95% | -3.10% | -2.15% | -19.03% | -47.96% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 23, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 3.47 | 3.38 | 3.88 | 2.03 | 2.89 | 3.23 |